1. Pityriasis lichenoides chronica after BNT162b2 Pfizer‐BioNTech vaccine: A novel cutaneous reaction after SARS‐CoV‐2 vaccine.
- Author
-
Drago, F., Ciccarese, G., Guadagno, A., and Parodi, A.
- Subjects
- *
COVID-19 vaccines , *RUBELLA , *COVID-19 , *ROSACEA - Abstract
PL, both in acute and chronic form, has previously been described following anti-tetanus-diphtheria, measles-mumps-rubella and influenza vaccination.7-9 PL following SARS-CoV-2 vaccination may occur as a delayed hypersensitivity response against vaccine excipients or SARS-CoV-2 spike glycoprotein or through a molecular mimicry mechanism between a viral epitope and host proteins resulting in a T-cell-mediated hypersensitivity skin reaction.10 In conclusion, we described a case of PL following SARS-CoV-2 vaccine never described before. Pityriasis lichenoides chronica after BNT162b2 Pfizer-BioNTech vaccine: A novel cutaneous reaction after SARS-CoV-2 vaccine Dear Editor, We read with interest the review from Gambichler I et al i .1 about cutaneous reactions following coronavirus disease 2019 (COVID-19) vaccination that prompted us to describe a cutaneous reaction after the mRNA vaccine Comirnaty SP ® sp (BNT162b2, Pfizer-BioNTech) that has never been reported before. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF